174 related articles for article (PubMed ID: 37373167)
1. CD276 as a Candidate Target for Immunotherapy in Medullary Thyroid Cancer.
Hińcza-Nowak K; Kowalik A; Walczyk A; Pałyga I; Gąsior-Perczak D; Płusa A; Kopczyński J; Chrapek M; Góźdź S; Kowalska A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373167
[TBL] [Abstract][Full Text] [Related]
2. Immune Profiling of Medullary Thyroid Cancer-An Opportunity for Immunotherapy.
Hińcza-Nowak K; Kowalik A; Walczyk A; Pałyga I; Gąsior-Perczak D; Płusa A; Kopczyński J; Chrapek M; Góźdź S; Kowalska A
Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680929
[TBL] [Abstract][Full Text] [Related]
3. Reduced Retinoblastoma Protein Expression Is Associated with Decreased Patient Survival in Medullary Thyroid Cancer.
Valenciaga A; Grubbs EG; Porter K; Wakely PE; Williams MD; Cote GJ; Vasko VV; Saji M; Ringel MD
Thyroid; 2017 Dec; 27(12):1523-1533. PubMed ID: 29105562
[TBL] [Abstract][Full Text] [Related]
4. Medullary thyroid carcinoma: a narrative historical review.
Wong A; Nabata K; Wiseman SM
Expert Rev Anticancer Ther; 2022 Aug; 22(8):823-834. PubMed ID: 35694971
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules.
Rieu M; Lame MC; Richard A; Lissak B; Sambort B; Vuong-Ngoc P; Berrod JL; Fombeur JP
Clin Endocrinol (Oxf); 1995 May; 42(5):453-60. PubMed ID: 7621562
[TBL] [Abstract][Full Text] [Related]
6. Analytical Performance of a Gene Expression Classifier for Medullary Thyroid Carcinoma.
Pankratz DG; Hu Z; Kim SY; Monroe RJ; Wong MG; Traweek ST; Kloos RT; Walsh PS; Kennedy GC
Thyroid; 2016 Nov; 26(11):1573-1580. PubMed ID: 27605259
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Immune Profiling of Medullary Thyroid Cancer.
Pozdeyev N; Erickson TA; Zhang L; Ellison K; Rivard CJ; Sams S; Hirsch FR; Haugen BR; French JD
Thyroid; 2020 Sep; 30(9):1263-1279. PubMed ID: 32242507
[No Abstract] [Full Text] [Related]
8. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
Dabelić N; Jukić T; Fröbe A
Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
[TBL] [Abstract][Full Text] [Related]
9. Early Diagnosis of Medullary Thyroid Cancer: Are Calcitonin Stimulation Tests Still Indicated in the Era of Highly Sensitive Calcitonin Immunoassays?
Niederle MB; Scheuba C; Riss P; Selberherr A; Koperek O; Niederle B
Thyroid; 2020 Jul; 30(7):974-984. PubMed ID: 32056502
[No Abstract] [Full Text] [Related]
10. Expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinase 2 (TIMP-2) in medullary thyroid carcinoma: prognostic implications.
Cavalheiro BG; Junqueira CR; Brandão LG
Thyroid; 2008 Aug; 18(8):865-71. PubMed ID: 18651826
[TBL] [Abstract][Full Text] [Related]
11. A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer.
Del Rivero J; Donahue RN; Marté JL; Gramza AW; Bilusic M; Rauckhorst M; Cordes L; Merino MJ; Dahut WL; Schlom J; Gulley JL; Madan RA
Front Endocrinol (Lausanne); 2020; 11():490. PubMed ID: 32849281
[TBL] [Abstract][Full Text] [Related]
12. Fine-needle aspiration cytology for medullary thyroid carcinoma: a single institutional experience in Japan.
Suzuki A; Hirokawa M; Takada N; Higuchi M; Ito A; Yamao N; Hayashi T; Kuma S; Miyauchi A
Endocr J; 2017 Nov; 64(11):1099-1104. PubMed ID: 28883261
[TBL] [Abstract][Full Text] [Related]
13. Quantitative Proteomics Analysis of Sporadic Medullary Thyroid Cancer Reveals FN1 as a Potential Novel Candidate Prognostic Biomarker.
Zhan S; Li J; Wang T; Ge W
Oncologist; 2018 Dec; 23(12):1415-1425. PubMed ID: 29739896
[TBL] [Abstract][Full Text] [Related]
14. Serum Calcitonin-Negative Medullary Thyroid Carcinoma: A Case Series of 19 Patients in a Single Center.
Kim SJ; Yun HJ; Shin SJ; Lee YS; Chang HS
Front Endocrinol (Lausanne); 2021; 12():747704. PubMed ID: 34803914
[TBL] [Abstract][Full Text] [Related]
15. Brain metastasis from calcitonin-negative medullary thyroid carcinoma.
Baptista PF; Fonseca LCM; Carvalho AFC; Silva SNVD; Freitas CRO
Ann Endocrinol (Paris); 2022 Aug; 83(4):258-260. PubMed ID: 35537523
[TBL] [Abstract][Full Text] [Related]
16. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin.
Zhou Q; Yue S; Cheng Y; Jin J; Xu H
Exp Toxicol Pathol; 2017 Oct; 69(8):575-579. PubMed ID: 28552629
[TBL] [Abstract][Full Text] [Related]
17. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
[TBL] [Abstract][Full Text] [Related]
18. [Medullary thyroid carcinoma].
Tiedje V; Ting S; Dralle H; Schmid KW; Führer D
Internist (Berl); 2015 Sep; 56(9):1019-31. PubMed ID: 26338063
[TBL] [Abstract][Full Text] [Related]
19. Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies.
Yeh T; Yeung M; Sherman EJ; Tuttle RM; Sabra MM
Thyroid; 2020 Aug; 30(8):1112-1119. PubMed ID: 32131709
[No Abstract] [Full Text] [Related]
20. Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations.
Barletta JA; Nosé V; Sadow PM
Endocr Pathol; 2021 Mar; 32(1):35-43. PubMed ID: 33492588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]